Amgen (AMGN) Tops Q1 EPS by 30c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amgen (AMGN) Posts Solid Q1, All Eyes Now on Repatha CV Outcomes Trial - BMO Capital
April 29, 2016 7:57 AM EDTBMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $183.00). He notes while results were solid all eyes will be on the upcoming Repatha CV outcomes trial.
Somaiya commented, "AMGN... More
Amgen (AMGN) PT Raised to $186 at Leerink Partners
April 29, 2016 6:58 AM EDTLeerink Partners analyst Geoffrey Porges raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $179.00) following solid Q1 results but stopped short of upgrading the stock and maintained an Market Perform rating.
Porges commented, "Revenue of $5.527bn handily beat consensus by 5%, although it fell short of our estimate of $5.66bn by 2% (Exhibit 1). The main drivers of the revenue... More
